Get the Stockscreener App
0.0718
1.64%
-0.0012
After Hours:
.07
-0.0018
-2.51%
Petros Pharmaceuticals Inc Stock (PTPI) Latest News
PTPI stock plunges to 52-week low of $0.07 amid market challenges By Investing.com - Investing.com South Africa
PTPI stock plunges to 52-week low of $0.07 amid market challenges - Investing.com Australia
PTPI’s price-to-free cash flow ratio: How it affects investment decisions - US Post News
Internationally Published, Head-to-Head Data From India of Petros Pharmaceuticals' STENDRA(R) (Avanafil) Tablets Reported Improvement in Erectile Function Compared to Sildenafil and Baseline After 12 Weeks of Therapy - ACCESS Newswire
Petros Pharmaceuticals Reports Record Revenue and Gross Profit During Second Quarter 2022 - ACCESS Newswire
New FDA-Approved Labeling for Petros Pharmaceuticals’ STENDRA (avanafil) Now Includes Efficacy Data Regarding Use in Men Who Have Undergone Radical Prostatectomy - ACCESS Newswire
Petros Pharmaceuticals stock hits 52-week low at $0.1 By Investing.com - Investing.com South Africa
Petros Pharmaceuticals stock hits 52-week low at $0.1 - Investing.com
Artificial Intelligence (AI) News Live Feed - StockTitan
Petros reports success in AI-assisted Rx-to-OTC study - Investing.com India
Petros reports success in AI-assisted Rx-to-OTC study By Investing.com - Investing.com South Africa
Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study - ACCESS Newswire
Can Petros Pharmaceuticals' AI-Powered Platform Revolutionize the $38B Self-Care Market? - StockTitan
PTPI Page Not Found - Benzinga
Petros Pharmaceuticals announces pricing of $9.6 million public offering - MSN
Form 424B4 Petros Pharmaceuticals, - StreetInsider.com
PTPI stock plunges to 52-week low of $0.15 amid market challenges - Investing.com India
Crude Oil Gains 1.5%; Fluor Shares Plunge Following Downbeat Earnings - Benzinga
Watsco, Septerna, Nike - TradingView
Petros Pharmaceuticals Prices $9.6 Million Public Offering of Shares, Warrants -February 18, 2025 at 09:52 am EST - Marketscreener.com
US Stocks Mixed; NY State Business Activity Rises In February - Benzinga India
Petros Pharmaceuticals sets public offering at $0.24 per share - Investing.com
Petros Pharmaceuticals prices 40M shares at 24c in public offering - TipRanks
Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and Warrants - ACCESS Newswire
Major Capital Raise: Petros Pharmaceuticals Locks $9.6M Financing DealStrategic Move or Dilution Risk? - StockTitan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Petros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference - ACCESS Newswire
Best Penny Stocks for Today (Charts Updated Daily) - Benzinga
Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider - ACCESS Newswire
Petros Pharmaceuticals (NASDAQ:PTPI) Trading 5.2% Higher – Still a Buy? - Defense World
Erectile Dysfunction Treatment Drugs Market to Hit USD 5.97 Billion by 2032, Growing at a 6.84% CAGR - EIN News
Analytical Lens: Exploring Perella Weinberg Partners (PWP)’s Financial Story Through Ratios - The Dwinnex
Balance Sheet Breakdown: Petros Pharmaceuticals Inc (PTPI)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Petros Pharmaceuticals Inc’s (PTPI) Stock: A Week-by-Week Analysis - The News Heater
Petros Pharmaceuticals Announces Capital Raise of $15 Million - ACCESS Newswire
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil) - ACCESS Newswire
Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules - ACCESS Newswire
Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status - ACCESS Newswire
Johnson & Johnson posts Q4 beat as drug sales offset MedTech weakness - MSN
Petros Pharmaceuticals modifies terms with investors By Investing.com - Investing.com India
Harmony Biosciences chief commercial officer sells shares worth $1.15m - MSN
Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider - ACCESS Newswire
Microvast files for $250M mixed securities shelf offering - MSN
Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually - ACCESS Newswire
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor’s (rosuvastatin) OTC Switch Technology Provider - ACCESS Newswire
Janbelco BV trims stake in Thalassa Holdings - MSN
Immedica to buy Marinus Pharmaceuticals for $151m - MSN
XORTX Therapeutics Announces Auditor Transition - MSN
Apellis Pharmaceuticals executive sells $36,998 in stock - MSN
Amneal gets FDA approval for generic Byetta, resubmits DHE NDA - MSN
Pharming Group appoints former Novartis USA President Fabrice Chouraqui as New CEO - MSN
Takeda-backed Ascentage Pharma targets $1.75 billion valuation in US IPO - MSN
Vincerx Pharma enters at-the-market equity offering deal - MSN
Mitsubishi Chemical picks Bain as preferred bidder for pharma unit, sources say - MSN
Sanofi receives GMP warning letter for Genzyme facility - MSN
Sinopharm Accord Projects Notable Profit Decline for 2024 - MSN
Comparing Petros Pharmaceuticals (NASDAQ:PTPI) & MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
AstraZeneca's Calquence gains FDA nod for 1L MCL treatment - MSN
FDA grants tentative approval for Amneal generic of Bausch Health's Xiafan - MSN
0.19%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):